Stock listing
NASDAQ:LNAI Lunai Bioworks Inc. Stock
Home listing (NASDAQ) of Lunai Bioworks Inc.
Follow Lunai Bioworks Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LNAI
$0.165 USD -0.071 (-30.2%)
Close on Oct 29, 2026
- Day range
- $0.147 – $0.230 USDOct 29, 2026
- Volume
- 957,123 sharesOct 29, 2026
- Market cap
- —Left out: price × shares is far from the company's reported size
- Traded on an average day
- $473,891 USDMedian day 40,400 shares · last 3 months, Jul 29, 2026 – Oct 29, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LNAI · Home | $0.165 USD | -0.071 (-30.2%) | 957,123 | $0.229 | $0.230 | $0.147 | $0.236 | Close on Oct 29, 2026 |
Daily closes
Last 3 months, Jul 29, 2026 – Oct 29, 2026 · NASDAQ:LNAI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.165 | -0.071 | -30.2% | $0.229 | $0.230 | $0.147 | 957,123 | |
| $0.236 | -0.017 | -6.7% | $0.221 | $0.250 | $0.202 | 622,800 | |
| $0.253 | -0.022 | -8.0% | $0.258 | $0.270 | $0.240 | 521,300 | |
| $0.275 | -0.020 | -6.8% | $0.263 | $0.302 | $0.233 | 614,600 | |
| $0.295 | -0.175 | -37.2% | $0.260 | $0.316 | $0.227 | 9,584,100 | |
| $0.470 | -0.048 | -9.3% | $0.530 | $0.530 | $0.460 | 174,300 | |
| $0.518 | +0.003 | +0.6% | $0.500 | $0.545 | $0.500 | 90,400 | |
| $0.515 | +0.043 | +9.1% | $0.490 | $0.580 | $0.472 | 216,900 | |
| $0.472 | -0.208 | -30.6% | $0.695 | $0.695 | $0.462 | 202,700 | |
| $0.680 | -0.146 | -17.7% | $0.812 | $0.812 | $0.660 | 79,900 | |
| $0.826 | -0.066 | -7.4% | $0.865 | $0.917 | $0.818 | 37,800 | |
| $0.892 | -0.138 | -13.4% | $0.999 | $1.005 | $0.892 | 69,400 | |
| $1.030 | -0.080 | -7.2% | $1.090 | $1.090 | $1.010 | 46,000 | |
| $1.110 | -0.120 | -9.8% | $1.290 | $1.290 | $1.050 | 97,200 | |
| $1.230 | +0.110 | +9.8% | $1.170 | $1.680 | $0.876 | 853,300 | |
| $1.120 | +0.030 | +2.8% | $1.140 | $1.150 | $1.100 | 14,800 | |
| $1.090 | -0.040 | -3.5% | $1.190 | $1.190 | $1.080 | 20,000 | |
| $1.130 | -0.010 | -0.9% | $1.130 | $1.200 | $1.130 | 23,600 | |
| $1.140 | -0.160 | -12.3% | $1.250 | $1.300 | $1.140 | 69,000 | |
| $1.300 | -0.080 | -5.8% | $1.440 | $1.460 | $1.230 | 124,900 | |
| $1.380 | -0.090 | -6.1% | $1.540 | $1.600 | $1.375 | 38,200 | |
| $1.470 | -0.300 | -16.9% | $1.890 | $1.890 | $1.385 | 102,200 | |
| $1.770 | -0.090 | -4.8% | $1.910 | $1.950 | $1.750 | 54,100 | |
| $1.860 | -0.070 | -3.6% | $2.050 | $2.050 | $1.810 | 41,000 | |
| $1.930 | -0.010 | -0.5% | $2.000 | $2.202 | $1.900 | 28,900 | |
| $1.940 | -0.200 | -9.3% | $2.185 | $2.185 | $1.930 | 45,000 | |
| $2.140 | -0.090 | -4.0% | $2.300 | $2.370 | $2.100 | 51,800 | |
| $2.230 | -0.070 | -3.0% | $2.660 | $2.670 | $2.220 | 211,400 | |
| $2.300 | -0.030 | -1.3% | $2.390 | $2.432 | $2.230 | 13,700 | |
| $2.330 | +0.055 | +2.4% | $2.270 | $2.360 | $2.260 | 16,700 | |
| $2.275 | +0.105 | +4.8% | $2.250 | $2.387 | $2.237 | 28,500 | |
| $2.170 | -0.020 | -0.9% | $2.150 | $2.310 | $2.150 | 30,600 | |
| $2.190 | +0.020 | +0.9% | $2.190 | $2.250 | $2.100 | 20,400 | |
| $2.170 | -0.210 | -8.8% | $2.400 | $2.610 | $2.151 | 30,700 | |
| $2.380 | -0.055 | -2.3% | $2.501 | $2.522 | $2.311 | 27,200 | |
| $2.435 | -0.175 | -6.7% | $2.570 | $2.570 | $2.435 | 3,000 | |
| $2.610 | +0.010 | +0.4% | $2.640 | $2.730 | $2.550 | 67,500 | |
| $2.600 | +0.210 | +8.8% | $2.390 | $2.929 | $2.390 | 60,800 | |
| $2.390 | +0.040 | +1.7% | $2.310 | $2.400 | $2.301 | 12,500 | |
| $2.350 | -0.050 | -2.1% | $2.376 | $2.390 | $2.230 | 44,700 | |
| $2.400 | +0.250 | +11.6% | $2.150 | $2.490 | $2.150 | 54,500 | |
| $2.150 | -0.125 | -5.5% | $2.260 | $2.330 | $2.150 | 22,600 | |
| $2.275 | -0.095 | -4.0% | $2.375 | $2.420 | $2.250 | 30,300 | |
| $2.370 | +0.020 | +0.9% | $2.350 | $2.435 | $2.280 | 35,200 | |
| $2.350 | -0.050 | -2.1% | $2.490 | $2.498 | $2.340 | 39,800 | |
| $2.400 | +0.200 | +9.1% | $2.200 | $2.480 | $2.200 | 69,800 | |
| $2.200 | +0.070 | +3.3% | $2.130 | $2.265 | $2.130 | 10,100 | |
| $2.130 | -0.025 | -1.2% | $2.160 | $2.230 | $2.100 | 34,900 | |
| $2.155 | -0.045 | -2.0% | $2.250 | $2.280 | $2.150 | 26,500 | |
| $2.200 | -0.020 | -0.9% | $2.152 | $2.260 | $2.150 | 18,600 | |
| $2.220 | +0.055 | +2.5% | $2.120 | $2.290 | $2.120 | 19,500 | |
| $2.165 | -0.085 | -3.8% | $2.240 | $2.240 | $2.150 | 20,000 | |
| $2.250 | +0.030 | +1.4% | $2.250 | $2.300 | $2.160 | 30,900 | |
| $2.220 | -0.020 | -0.9% | $2.250 | $2.250 | $2.150 | 33,700 | |
| $2.240 | -0.110 | -4.7% | $2.350 | $2.360 | $2.200 | 44,600 | |
| $2.350 | -0.050 | -2.1% | $2.390 | $2.410 | $2.260 | 218,600 | |
| $2.400 | +0.040 | +1.7% | $2.330 | $2.473 | $2.330 | 30,500 | |
| $2.360 | -0.050 | -2.1% | $2.450 | $2.450 | $2.300 | 23,200 | |
| $2.410 | -0.010 | -0.4% | $2.400 | $2.550 | $2.390 | 37,600 | |
| $2.420 | -0.060 | -2.4% | $2.440 | $2.480 | $2.360 | 56,600 | |
| $2.480 | -0.070 | -2.7% | $2.510 | $2.750 | $2.371 | 103,200 | |
| $2.550 | +0.160 | +6.7% | $2.160 | $3.200 | $2.135 | 845,200 | |
| $2.390 | +0.450 | +23.2% | $2.000 | $3.780 | $1.910 | 8,102,900 | |
| $1.940 | -0.080 | -4.0% | $2.050 | $2.130 | $1.940 | 26,500 | |
| $2.020 | -0.090 | -4.3% | $2.060 | $2.105 | $2.000 | 23,300 | |
| $2.110 | -0.130 | -5.8% | $2.170 | $2.200 | $2.060 | 15,100 |
Splits
1 split · NASDAQ:LNAI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-8 | Consolidation |
- Ticker
- NASDAQ:LNAI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 22, 2026
Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
Latest deck · January 2026
Investor Presentation (January 2026)
Investor deck · 27 slides
Latest news
Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
Oct 22, 2026
Closed $0.295 (-37.2%) on Oct 23, 2026
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
Sep 22, 2026
Closed $2.23 (-3.0%) on Sep 22, 2026
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
Sep 16, 2026
Closed $2.17 (-0.9%) on Sep 16, 2026
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
Aug 27, 2026
Closed $2.35 (-2.1%) on Aug 27, 2026
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
Aug 4, 2026
Closed $2.55 (+6.7%) on Aug 4, 2026
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
Aug 4, 2026
Closed $2.55 (+6.7%) on Aug 4, 2026
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
May 28, 2026
Closed $3.04 (+16.0%) on May 28, 2026
Lunai Bioworks Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 30 in all · newest Oct 22, 2026 · oldest 2025
- Decks
- 8 decks · latest January 2026
Where Lunai Bioworks Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LNAI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LNAI | BOATS | United States | USD |
| gettex:2Q50 | gettex | Germany | EUR |
| Lang & Schwarz:A41K8P | Lang & Schwarz | Germany | EUR |
| Frankfurt:2Q50 | Frankfurt | Germany | EUR |
| LS Exchange:A41K8P | LS Exchange | Germany | EUR |
| Munich:2Q50 | Munich | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Oct 29, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- 50.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.33
Team and board
Officers
| Officer | Role |
|---|---|
| David Weinstein | Director & Chief Executive Officer |
| Emily Doe | Director of Machine Learning Operations |
| Emily Smith | Director of Machine Learning Operations |
| Emily Wang | Director of Machine Learning Operations |
| Ethan Doe | Head of AI Research and Development |
| Ethan Turner | Head of AI Research and Development |
| Jane Wang | Director of Machine Learning Operations |
| Sophia Doe | Director of Machine Learning Operations |
| Sophia Patel | Director of Machine Learning Operations |
Board
| Director | Role |
|---|---|
| David Weinstein | Director & Chief Executive Officer |
| Douglas W. Calder | Director |
| James A. McNulty | Director |
| Mark A. Collins | Director |
Events
| Quarter | Results |
|---|---|
| Q1 2027 | Nov 13, 2026 |
| Q3 2026 | May 14, 2026 · After close |
| Q2 2026 | Feb 17, 2026 · After close |
| Q1 2026 | Nov 17, 2025 · After close |
| Q4 2025 | Sep 29, 2025 |
| Q3 2025 | May 15, 2025 |
| Q2 2025 | Feb 19, 2025 |
| Q3 2023 | May 12, 2023 |
| Q2 2023 | Feb 27, 2023 |
| Q3 2022 | May 13, 2022 |
All 15 quarters
| Quarter | Results |
|---|---|
| Q2 2022 | Feb 14, 2022 |
| Q1 2022 | Nov 15, 2021 |
| Quarter to Jun 30, 2021 | Sep 24, 2021 |
| Quarter to Mar 31, 2021 | May 17, 2021 |
| Quarter to Dec 31, 2020 | Feb 16, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 27 slides | January 2026 |
| Investor Presentation (January 2026) | Investor deck | 31 slides | January 2026 |
| Investor Presentation (January 2026) | Investor deck | 31 slides | January 2026 |
| Renovaro Biosciences — Investor Presentation (January 2024) | Investor deck | 28 slides | Jan 16, 2024 |
| Renovaro Biosciences — Investor Presentation (August 2023) | Investor deck | 43 slides | Aug 7, 2023 |
| Enochian Biosciences — Innate Killer Summit 2023 | Conference | 10 slides | Mar 28, 2023 |
| Enochian Biosciences — Investor Presentation (October 2022) | Investor deck | 39 slides | Oct 14, 2022 |
| Innate Killer Summit 2022 | Conference | 17 slides | March 2022 |
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.0K | 0 | 0 | 0 | 0 | |||||
| Cost of revenue | 93.5K | 129.1K | 391.4K | |||||||
| Gross profit | -41.5K | -129.1K | 0 | 0 | -391.4K | |||||
| Research and development | 24.5K | 537.4K | 2.71M | 4.17M | 8.37M | 15.7M | 4.69M | 2.50M | 617.0K | 62.8K |
| Selling, general and administrative | 7.80B | 17.9M | 24.6M | 15.3M | 14.3M | |||||
| Operating income | -8.70M | -189.0M | -81.6M | -38.6M | -116.1M | -23.4M | -11.9M | -11.0M | -5.33M | -2.40M |
| Depreciation and amortization | 93.5K | 129.1K | 121.9K | 113.5K | 123.6K | 123.5K | 108.6K | 71.7K | 18.5K | 14.5K |
| EBITDA | -8.60M | -188.8M | -81.5M | -38.4M | -116.0M | -23.3M | -11.8M | -10.9M | -5.31M | -2.39M |
| Interest expense | 235.1K | 725.7K | 1.01M | 580.3K | 372.8K | 379.6K | 104.3K | 43 | 143.3K | |
| Income before tax | -3.56M | -178.0M | -88.4M | -39.7M | -113.4M | -26.8M | -11.4M | -18.0M | -6.42M | -2.21M |
| Income tax | 1.41K | 1.47K | 0 | 34 | -125.3K | -111.7K | -64.9K | |||
| Net income | -3.56M | -178.0M | -88.4M | -39.7M | -113.4M | -26.7M | -11.4M | -18.0M | -6.31M | -2.14M |
| Earnings per share, basic | -1.06 | -86.27 | -0.91 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 |
| Earnings per share, diluted | -1.06 | -86.27 | -0.91 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.71M | 92.7K | 220.5K | 1.87M | 9.17M | 20.7M | 8.70M | 12.3M | 15.6M | 3.94M |
| Short-term investments | 0 | 387.9K | 0 | |||||||
| Receivables | 1.11M | 1.64K | ||||||||
| Current assets | 2.04M | 1.05M | 2.00M | 2.57M | 9.57M | 20.9M | 8.94M | 12.5M | 15.8M | 4.20M |
| Property, plant and equipment | 12.0K | 367.8K | 482.1K | 509.0K | 586.5K | 719.4K | 778.1K | 687.5K | 27.4K | |
| Goodwill | 5.96M | 5.96M | 159.3M | 11.6M | 11.6M | 11.6M | 11.6M | 11.6M | 11.6M | |
| Total assets | 9.94M | 8.23M | 163.1M | 58.3M | 84.6M | 189.6M | 178.1M | 179.9M | 182.5M | 4.52M |
| Accounts payable | 12.4M | 12.6M | 9.45M | 5.30M | 1.40M | 320.6K | ||||
| Current liabilities | 18.9M | 29.2M | 30.3M | 11.0M | 6.45M | 1.89M | 1.33M | 1.11M | 873.7K | 2.99M |
| Long-term debt | 4.58M | |||||||||
| Total debt | 1.34M | 10.2M | 3.79M | 5.59M | 7.02M | 7.37M | ||||
| Total liabilities | 19.0M | 29.6M | 31.2M | 11.8M | 12.0M | 14.9M | 11.8M | 6.78M | 23.8M | 2.99M |
| Shareholders' equity | -9.02M | -21.3M | 132.0M | 46.5M | 72.6M | 174.7M | 166.3M | 173.1M | 158.7M | 1.53M |
| Shares outstanding | 4.62M | 2.22M | 158.5M | 63.7M | 53.0M | 52.2M | 46.5M | 45.3M | 36.2M | 12.4M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.29M | -7.87M | -11.0M | -11.8M | -15.7M | -20.6M | -10.5M | -8.51M | -4.34M | -1.18M |
| Capital spending | -1.24K | -3 | -70.4K | -29.8K | -5.16K | -48.9K | -184.5K | -716.7K | -30.0K | |
| Free cash flow | -5.29M | -7.87M | -11.0M | -11.8M | -15.7M | -20.7M | -10.6M | -9.22M | -4.37M | |
| Cash from investing | 543.5K | -500.0K | -1.26M | -29.8K | -5.16K | -48.9K | -184.5K | -716.7K | -575.7K | -196.1K |
| Cash from financing | 6.39M | 8.38M | 10.5M | 4.52M | 4.25M | 32.6M | 7.20M | 6.02M | 16.7M | 5.51M |
| Change in cash | 1.62M | -127.8K | -1.65M | -7.30M | -11.5M | 12.0M | -3.59M | -3.32M | 11.7M | 3.92M |
Cap table
Built by 6ix from Lunai Bioworks Inc.’s releases
- Common shares
- 5,034,452
- Fully diluted
- 5,034,452
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,034,452 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,034,452 |
| May 20, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Sapirstein Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); Cocrystal Pharma, Inc. (Chief Executive Officer · Since at least Jun 3, 2026); ZyVersa Therapeutics, Inc. (Director · Since at least Jan 5, 2023); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Hepion Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 3, 2018 · Past); RespireRx Pharmaceuticals Inc (Director · Dec 9, 2017 – Dec 9, 2017 · Past) | Director · Mar 6, 2018 – Jun 25, 2024 · Past |
| An Evelyn D Other companies: Backblaze, Inc. (Director · Since at least Nov 10, 2021); Matinas BioPharma Holdings, Inc. (Director · Feb 5, 2025 – Apr 30, 2025 · Past); Zoomcar Holdings Inc (Director · Dec 28, 2023 – Dec 28, 2023 · Past); Summer Infant Inc (Director · Nov 2, 2016 – Jun 22, 2022 · Past); Hot Topic Inc (Director · Jun 14, 2007 – Jun 12, 2013 · Past); Alico, Inc. (Director · Mar 28, 2006 – Jan 13, 2010 · Past) | Director · Mar 6, 2018 – Mar 6, 2021 · Past |
| Carol Brosgart Other companies: Cocrystal Pharma, Inc. (Director · Since at least Aug 12, 2026); Galmed Pharmaceuticals Ltd. (Director · Since at least Mar 18, 2026); Mirum Pharmaceuticals, Inc. (Director · Jun 4, 2021 – Jun 2, 2022 · Past); Tobira Therapeutics Inc (Director · Jul 9, 2015 – Nov 1, 2016 · Past) | Director · Dec 27, 2019 – Jun 25, 2024 · Past |
| James A. McNulty Other companies: Inhibitor Therapeutics Inc. (Chief Financial Officer · Since at least Dec 13, 2022); CV Sciences, Inc. (Director · Feb 5, 2018 – Jun 16, 2020 · Past) | Director · Since at least Oct 14, 2024 |
| Leni Boeren Other companies: Aegon Ltd. (Member of Compensation & Human Resource Committee · Since at least Apr 29, 2026) | Director · Oct 4, 2023 – Oct 4, 2023 · Past |
| Samir Naji Masri Other companies: Intra-Cellular Therapies Inc (CEO, CFO, Pres & Secretary, Director · Apr 9, 2013 – Apr 9, 2013 · Past) | See Remarks, Director · Oct 11, 2011 – Oct 11, 2011 · Past |
| Simon Tarsh Other companies: Onconetix, Inc. (Director · Since at least Aug 22, 2022) | Interim CFO · Mar 11, 2024 – Nov 4, 2024 · Past |
| Anderson Wittekind William | Director · Dec 31, 2018 – Dec 31, 2018 · Past |
| Avram Miller | Director · Oct 11, 2023 – Aug 23, 2024 · Past |
| David Weinstein | Director & Chief Executive Officer · Since at least Oct 14, 2024 |
All 26 people
| Person | Seat |
|---|---|
| Douglas W. Calder | Director · Since at least Nov 5, 2026 |
| Emily Doe | Director of Machine Learning Operations · Since at least Nov 4, 2026 |
| Emily Smith | Director of Machine Learning Operations · Since at least Nov 4, 2026 |
| Emily Wang | Director of Machine Learning Operations · Since at least Nov 4, 2026 |
| Ethan Doe | Head of AI Research and Development · Since at least Nov 4, 2026 |
| Ethan Turner | Head of AI Research and Development · Since at least Nov 4, 2026 |
| Henrik Gronfeldt-Sorensen | Director · Oct 11, 2021 – Oct 9, 2023 · Past |
| Jane Wang | Director of Machine Learning Operations · Since at least Nov 4, 2026 |
| Jayne McNicol | Director · May 26, 2021 – Jun 25, 2024 · Past |
| Karen Brink | Director · Feb 23, 2024 – Aug 12, 2024 · Past |
| Luisa Puche | Chief Financial Officer · Jan 7, 2019 – Feb 13, 2024 · Past |
| Mark A. Collins | Director · Since at least Oct 14, 2024 |
| Mark Dybul | Chief Executive Officer, Director · Dec 14, 2020 – Feb 13, 2024 · Past |
| Rene Sindlev | Director · Jul 17, 2017 – Jun 25, 2024 · Past |
| Sophia Doe | Director of Machine Learning Operations · Since at least Nov 4, 2026 |
| Sophia Patel | Director of Machine Learning Operations · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Lunai Bioworks Inc.